Fortis Malar Hospitals (BOM:523696) Research & Development: ₹0.00 Mil (TTM As of Mar. 2026)


BOM:523696 Fortis Malar Hospitals Ltd BOM:523696
32 GF Score
Price ₹51.78
GF Value ₹0.03
Valuation Significantly Overvalued
View Full Analysis

What is Fortis Malar Hospitals Research & Development?

Fortis Malar Hospitals BOM:523696 -0.61% 32 Research & Development is ₹0.00 Mil as of Mar. 2026. GuruFocus rates BOM:523696 with a GF Score™ of 32/100 and a GF Value™ of ₹0.03 (Significantly Overvalued).

Research & Development is the aggregate amount of research and development expenses during the year. Fortis Malar Hospitals's Research & Development for the three months ended in Mar. 2026 was ₹0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0.00 Mil.

Fortis Malar Hospitals  (BOM:523696) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Fortis Malar Hospitals Research & Development Related Terms

Fortis Malar Hospitals Research & Development Historical Data

* Premium members only.

The historical data trend for Fortis Malar Hospitals's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fortis Malar Hospitals Research & Development Chart

Fortis Malar Hospitals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Fortis Malar Hospitals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BOM:523696
32GF Score
Fortis Malar Hospitals Ltd BOM:523696
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Fortis Malar Hospitals Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ₹0.00 Mil mean?
Fortis Malar Hospitals (BOM:523696) has a Research & Development of ₹0.00 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Fortis Malar Hospitals and its competitors.
Is Fortis Malar Hospitals' Research & Development too high?
Fortis Malar Hospitals' current Research & Development is ₹0.00 Mil. Overall, Fortis Malar Hospitals has a GF Score™ of 32/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Fortis Malar Hospitals' Research & Development compare to HCA and THC?
Fortis Malar Hospitals' Research & Development of ₹0.00 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Fortis Malar Hospitals and its competitors. Fortis Malar Hospitals's current Research & Development is ₹0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fortis Malar Hospitals stock overvalued right now?
Based on GuruFocus' analysis, Fortis Malar Hospitals (BOM:523696) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹0.03, compared to a current price of ₹51.78 — trading 172500% above its estimated fair value. The current Research & Development is ₹0.00 Mil. Fortis Malar Hospitals' overall GF Score™ is 32/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Fortis Malar Hospitals (BOM:523696), the current Research & Development is ₹0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fortis Malar Hospitals (BOM:523696) Overvalued in 2026?

Based on GuruFocus' analysis, Fortis Malar Hospitals stock appears to be overvalued. The current stock price of ₹51.78 is trading 172500% above its estimated GF Value™ of ₹0.03. GuruFocus considers Fortis Malar Hospitals to be Significantly Overvalued.

Key valuation signals for BOM:523696:

  • Research & Development: ₹0.00 Mil
  • GF Value™: ₹0.03 vs. price of ₹51.78 (172500% above fair value)
  • GF Score™: 32/100

No single metric tells the full story. See the BOM:523696 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Fortis Malar Hospitals Business Description

Address Fortis Hospital, Sector 62, Phase VIII, Mohali, PB, IND, 160062
Fortis Malar Hospitals Ltd is an India-based company engaged in the provision of healthcare services. It focuses on providing medical care in the areas of cardiology and cardiac surgery, neurosurgery, gynecology, orthopedics, gastroenterology, neurology, pediatrics, diabetes, nephrology, and internal medicine. The company provides healthcare services in various branches of medicine such as general surgery, general medicine, pediatrics, neurology, cardiology, ophthalmology, radiology, pathology, gastroenterology, urology, thoracic surgery, plastic surgery, and other allied specialties. It operates in one business, namely, in the health care services.
32GF Score

Get the complete analysis for BOM:523696

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹51.78
Price
₹0.03
GF Value